This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (21)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • External Eye Disease  • Alert me on articles by topic  Social Bookmarking   What's this?

Melissa L. Meldrum, MD; David T. Tse, MD; Pasquale Benedetto, MD

Arch Ophthalmol. 1998;116:315-321.

Objective  To investigate a new chemotherapeutic regimen as an adjunct to the conventional surgical management of patients with advanced adenocystic carcinoma of the lacrimal gland.

Patients and Methods  Two patients with extensive adenocystic carcinoma of the lacrimal gland were treated with intracarotid cisplatin and intravenous doxorubicin hydrochloride prior to orbital exenteration. Postoperatively, the patients received 55 to 60 Gy of orbital irradiation, augmented by additional intravenous cisplatin and doxorubicin. Serial clinical and computed tomographic scan examinations were performed to monitor for evidence of recurrent disease.

Results  Tumor shrinkage was documented radiographically following this preoperative chemotherapy regimen, downstaging the disease in one case from intracranial involvement to a more surgically amenable intraorbital process. Tumor necrosis was confirmed in the exenteration specimen. Limited morbidity was experienced and both patients have achieved long-term survival to date of 9 years (114 months) and 7 years (94 months).

Conclusions  To our knowledge, this is the first report of the efficacy of neoadjuvant intracarotid chemotherapy in the treatment of an advanced adenocystic carcinoma of the lacrimal gland. The combination of cisplatin and doxorubicin and the methods of drug delivery may be factors contributory to the favorable response. The results of this new treatment regimen are encouraging and justify further investigation.

From the Departments of Ophthalmology (Drs Meldrum and Tse) and Medicine (Dr Benedetto), University of Miami School of Medicine, Miami, Fla. The authors, their families, their employers, and their business associates have no financial or proprietary interest in any product or company associated with any device, instrument, or drug mentioned in this article. The authors have not received any payment as consultants, reviewers, or evaluators of any of the devices, instruments, or drugs mentioned in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Intra-arterial Chemotherapy: A Welcome New Idea for the Management of Adenocystic Carcinoma of the Lacrimal Gland
Robert Alan Goldberg
Arch Ophthalmol. 1998;116(3):372-373.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Mortality following exenteration for malignant tumours of the orbit
Rahman et al.
Br. J. Ophthalmol. 2005;89:1445-1448.
ABSTRACT | FULL TEXT  

Chemoreduction With Topical Mitomycin C Prior to Resection of Extensive Squamous Cell Carcinoma of the Conjunctiva
Shields et al.
Arch Ophthalmol 2005;123:109-113.
FULL TEXT  

Adenoid Cystic Carcinoma of the Lacrimal Gland Simulating a Dermoid Cyst in a 9-Year-Old Boy
Shields et al.
Arch Ophthalmol 1998;116:1673-1676.
ABSTRACT | FULL TEXT  

Inappropriate Use of the Term "Adenocystic" to Refer to "Adenoid Cystic" Carcinoma of the Lacrimal Gland
White
Arch Ophthalmol 1998;116:1698-1698.
FULL TEXT